ARF1 Double Nickase Plasmid (h): sc-401608-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ARF1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ARF1 Double Nickase Plasmid (h) and ARF1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ARF1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ARF1 Antibody (ARFS 1A9/5): sc-53168
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ARF1 Double Nickase Plasmid (h) | sc-401608-NIC | 20 µg | $410.00 | |||
ARF1 Double Nickase Plasmid (h2) | sc-401608-NIC-2 | 20 µg | $410.00 |
ADP-ribosylation factor 1 (ARF1) is a small GTPase that cycles between GDP- and GTP-bound states to regulate membrane trafficking and organelle dynamics, particularly at the Golgi apparatus and endosomal system. Active ARF1 recruits coat proteins and adaptors to drive vesicle budding, coordinates phosphoinositide metabolism, and supports cytoskeletal remodeling through downstream effectors. Through these roles, ARF1 contributes to secretory pathway flux, receptor recycling, and signal transduction linked to cell growth and migration. Dysregulated ARF1-dependent trafficking has been associated with altered proliferation and invasive phenotypes in cancer models and with perturbations of neuronal and immune cell function in disease-relevant contexts.
ARF1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ARF1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ARF1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ARF1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ARF1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.